ArticleMemorias do Instituto Oswaldo Cruz2019
Brazilian malaria molecular targets (BraMMT): selected receptors for virtual high-throughput screening experiments.
Article in Memorias do Instituto Oswaldo Cruz, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Advances in Developing Small Molecule Drugs for Alzheimer's Disease.Current Alzheimer research · 2024Review
- Rational-Based Discovery of Novel β-Carboline Derivatives as Potential Antimalarials: From In Silico Identification of Novel Targets to Inhibition of Experimental Cerebral Malaria.Pathogens (Basel, Switzerland) · 2022Article
- Antimicrobial activity of clioquinol and nitroxoline: a scoping review.Archives of microbiology · 2022Article
- Evaluation of antiplasmodial activity in silico and in vitro of N-acylhydrazone derivatives.BMC chemistry · 2022Article
- In vitro and in silico assessment of new beta amino ketones with antiplasmodial activity.Revista da Sociedade Brasileira de Medicina Tropical · 2022Article
- Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.International journal of molecular sciences · 2021Review
- Dehydrobufotenin extracted from the Amazonian toadThe journal of venomous animals and toxins including tropical diseases · 2021Article
- Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks.Pharmaceutics · 2020Article
- Article
- Structure-Based Virtual Screening: From Classical to Artificial Intelligence.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOwing to increased spending on pharmaceuticals since 2010, discussions about rising costs for the development of new medical technologies have been focused on the pharmaceutical industry. Computational techniques have been developed to reduce costs associated with new drug development. Among these techniques, virtual high-throughput screening (vHTS) can contribute to the drug discovery process by providing tools to search for new drugs with the ability to bind a specific molecular target.
objectivesIn this context, Brazilian malaria molecular targets (BraMMT) was generated to execute vHTS experiments on selected molecular targets of Plasmodium falciparum.
methodsIn this study, 35 molecular targets of P. falciparum were built and evaluated against known antimalarial compounds.
findingsAs a result, it could predict the correct molecular target of market drugs, such as artemisinin. In addition, our findings suggested a new pharmacological mechanism for quinine, which includes inhibition of falcipain-II and a potential new antimalarial candidate, clioquinol. MAIN
conclusionsThe BraMMT is available to perform vHTS experiments using OCTOPUS or Raccoon software to improve the search for new antimalarial compounds. It can be retrieved from www.drugdiscovery.com.br or download of Supplementary data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.